For a simplified snapshot from TREAT Asia/amfAR on ledipasvir and sofosbuvir co-formulation for the treatment of hepatitis C, please click here.
For a simplified snapshot from TREAT Asia/amfAR on daclatasvir, a second generation direct-acting antiviral for the treatment of hepatitis C, please click here.
For the latest on interactions and dose adjustments for antiretroviral for HIV and HCV Direct-acting antivirals, please click here.
Updated pricing list of Indian generic sofosbuvir as on 30 january 2016. For more details, click here.
Availability, manufacturer and pricing details of generic daclatasvir 60mg in India as on 30th January 2016. Click here for the full list.
Four Indian generic companies (Cipla, Emcure, Hetero and NATCO) takes sub-licenses from Medicines Patent pool (MPP) on Daclatasvir. The copy of the sub- licenses are not available yet, but please refer to the form for an outline. Long term implications of how this improves access in included territory or inhibits ...
A study on how generic competition can rapidly lower the prices of drugs with high hepatitis C cure rates, like sofosbuvir and daclatasvir and help achieve global treatment scale-up, 12th January, 2016 Click here for more details.
Pricing/manufacturer/marketer details for the Indian generic ledipasvir and sofosbuvir co-formulated tablets as on 10th January 2016. Click here to see the full list.
6 October 2015, Bangkok, Hanoi and Kuala Lumpur The Asia Pacific Network of People living with HIV/AIDS (APN+), Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) and the Vietnam Network of People living with HIV (VNP+) are expressing deep dismay at news of the conclusion of the Trans-Pacific Partnership Agreement (TPP) ...